Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines.

Abstract

Therapeutic DeliveryVol. 5, No. 7 EditorialOvercoming barriers in the mucosal delivery of virus-like particle-based vaccinesMelissa M Herbst-KralovetzMelissa M Herbst-KralovetzE-mail Address: mherbst1@email.arizona.eduDepartment of Basic Medical Sciences, College of Medicine – Phoenix; The University of Arizona, Building ABC-1, 425 North 5th St, Phoenix, AZ 85004 –2157, USASearch for more papers by this authorPublished Online:7 Oct 2014https://doi.org/10.4155/tde.14.52AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adjuvantdelivery devicemucoadhesive formulationmucosal delivery routemucosal immunizationmucosal vaccinenasaloralPRR agonistreproductive mucosavirus-like particleReferences1 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nature Medicine 11(4 Suppl.), S45–S53 (2005).Crossref, Google Scholar2 Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430–445 (2001).Crossref, Medline, CAS, Google Scholar3 Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 111(3), 425–440 (2014).Crossref, Medline, CAS, Google Scholar4 Mason HS, Herbst-Kralovetz MM. Plant-derived antigens as mucosal vaccines. Curr. Top. Microbiol. Immunol. 354, 101–120 (2012).Medline, CAS, Google Scholar5 Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vacc. 9(3), 299–307 (2010).Crossref, Medline, CAS, Google Scholar6 Ferreira RB, Antunes LC, Finlay BB. Should the human microbiome be considered when developing vaccines? PLoS Pathogens 6(11), e1001190 (2010).Crossref, Medline, Google Scholar7 Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nature Rev. Immunol. 6(2), 148–158 (2006).Crossref, Medline, CAS, Google Scholar8 Jackson EM, Herbst-Kralovetz MM. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PloS ONE 7(7), e41529 (2012).Crossref, Medline, CAS, Google Scholar9 Hjelm BE, Kilbourne J, Herbst-Kralovetz MM. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum. Vaccin. Immunother. 10(3), (2013).Medline, Google Scholar10 Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol. 354, 1–18 (2012).Medline, CAS, Google Scholar11 Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vacc. Immunol. CVI 17(12), 1850–1858 (2010).Crossref, Medline, Google Scholar12 Velasquez LS, Shira S, Berta AN et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29(32), 5221–5231 (2011).Crossref, Medline, CAS, Google Scholar13 Tomasi TB, Jr. Oral tolerance. Transplantation 29(5), 353–356 (1980).Crossref, Google Scholar14 Fraillery D, Zosso N, Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 27(17), 2326–2334 (2009).Crossref, Medline, CAS, Google Scholar15 Levine MM. 'IDEAL' vaccines for resource poor settings. Vaccine 29 Suppl 4, D116–125 (2011).Crossref, Medline, Google Scholar16 Azevedo MS, Gonzalez AM, Yuan L et al. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin. Vaccine Immunol. CVI 17(3), 420–428 (2010).Crossref, Medline, CAS, Google Scholar17 Quan FS, Ko EJ, Kwon YM, Joo KH, Compans RW, Kang SM.Mucosal adjuvants for influenza virus-like particle vaccine. Viral immunol. 26(6), 385–395 (2013).Crossref, Medline, CAS, Google Scholar18 Vacher G, Kaeser MD, Moser C, Gurny R, Borchard G.Recent advances in mucosal immunization using virus-like particles. Molecular pharmaceutics. 10(5), 1596–1609 (2013).Crossref, Medline, Google Scholar19 Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, Dealmeida DR, Ross TM.Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine. 29(48), 9081–9092 (2011).Crossref, Medline, Google Scholar20 El-Kamary SS, Pasetti MF, Mendelman PM et al.Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649–1358 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByThe Mucoadhesive Nanoparticle-Based Delivery System in the Development of Mucosal Vaccines1 September 2022 | International Journal of Nanomedicine, Vol. Volume 17Delivery strategies to enhance oral vaccination against enteric infectionsAdvanced Drug Delivery Reviews, Vol. 91 Vol. 5, No. 7 Follow us on social media for the latest updates Metrics Downloaded 61 times History Published online 7 October 2014 Published in print July 2014 Information© Future Science LtdKeywordsadjuvantdelivery devicemucoadhesive formulationmucosal delivery routemucosal immunizationmucosal vaccinenasaloralPRR agonistreproductive mucosavirus-like particleAcknowledgementsI would like to thank Dr Charles Arntzen and the past and current members of my laboratory for their support and thoughtful discussions on the topic of VLP-based vaccines.Financial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download